GE brings new imaging technology to
HAMILTON, Ont. – Hamilton was
selected by GE Healthcare to be the first site in the world to receive
new prototype technologies for use in a molecular breast imaging
research program. Hamilton researchers will design and lead clinical
trials to evaluate new technologies which use molecular imaging probes
that target breast cancer.
This cutting-edge strategy has the potential to find very small tumours,
leading to early intervention. Trials will be geared towards high-risk
women who are not currently well served by mammography.
GE Healthcare chose Hamilton because of the strong partnership among the
Ontario Institute for Cancer Research (http://www.oicr.on.ca/),
the Centre for Probe Development and Commercialization (http://www.imagingprobes.ca/),
and the Oncology and Nuclear Medicine programs at McMaster University (http://www.mcmaster.ca/home.cfm)
and Hamilton Health Sciences (http://www.hamiltonhealthsciences.ca/).
Ontario’s Ministry of Research and Innovation has committed almost $435
million since 2003 to support the world-leading work of these
institutions, and is contributing $450,000 toward the project through
the Ontario Institute for Cancer Research.
“The molecular breast imaging project is great news for Hamilton,
Ontario and Canada. Being the world’s first site to receive these GE
Healthcare technologies speaks to the expertise of our clinicians and
researchers,” said Murray Martin, President and Chief Executive Officer,
Hamilton Health Sciences. “It also symbolizes the power of what can be
achieved through collaboration between clinical, research, industry and
government partners in the interest of advancing knowledge to improve
“Our goal is for cancer to be diagnosed at the earliest stage,” said Dr.
Tom Hudson, President and Scientific Director, Ontario Institute for
Cancer Research. “These technologies may have a significant impact on
care for high-risk patients whose tiny tumours cannot be seen by
mammography. We hope this will lead to earlier detection, better
treatment and ultimately, save lives.”
Each year in Ontario, 8,500 women are diagnosed with breast cancer.
According to the Mayo Clinic, when localized breast cancer is caught at
an early stage, the survival rate is 98 percent.
“One of the global challenges in cancer is that it is diagnosed late in
the disease process, leading to a poorer outcome than when the tumour is
small. Our goal is to be able to detect a tumour when it can be removed
at an early stage,” said Dr. Hudson.
“We are supporting the Centre for Probe Development and
Commercialization, which is working on new radiopharmaceutical probes to
diagnose breast cancer,” said Dr. Hudson. “And we are funding this new
imaging project, which uses the CPDC’s probes, because the technologies
may have a significant impact on care. We hope that it will offer
patients with tumours too small to be seen by mammography, long-term
“At GE Healthcare, we are dedicated to early detection, and developing
technologies to better manage breast disease. We are thrilled with the
possibility of bringing to Ontario and to the CPDC a new breast imaging
technology platform, the first of its kind, to be utilized as part of
their clinical study,” said Peter Robertson, General Manager, GE
For its part, Ontario is the largest hub of life sciences activity in
Canada and the fourth largest biomedical research centre in North